Transaction DateRecipientSharesTypePriceValue
23rd June 2020Bryan Giraudo2,000Open or private purchase$12.96$25,922.40
14th May 2020Jakob Dupont46,250Grant/award etc.$0.00
14th February 2020Waage Christian46,500Grant/award etc.$0.00
14th February 2020Luisa Salter Cid46,500Grant/award etc.$0.00
14th February 2020Sheila Gujrathi189,500Grant/award etc.$0.00
14th February 2020Jakob Dupont46,500Grant/award etc.$0.00
14th February 2020Bryan Giraudo46,500Grant/award etc.$0.00
10th February 2020Venture Partners Ix, Llc Arch4,121,520Conversion of derivative$0.00
10th February 2020Kristina Burow4,121,519Conversion of derivative$0.00
10th February 2020Kristina Burow4,121,520Conversion of derivative$0.00
Gossamer Bio
Gossamer Bio logo

Gossamer Bio, Inc. engages in discovering, acquiring, developing, and commercializing therapeutics. Its primary product candidate is GB001, which is intended for the treatment of moderate-to-severe eosinophilic asthma. The company was founded by Faheem Hasnain and Sheila Gujrathi in 2015.

Ticker: GOSS
Sector: Health Technology
Industry: Pharmaceuticals: Major
SEC Central Index Key (CIK): 1728117
Employees: 171
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags